quetiapine has been researched along with Weight Gain in 3 studies
Weight Gain: Increase in BODY WEIGHT over existing weight.
Excerpt | Relevance | Reference |
---|
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 3 (100.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Kroeze, WK | 1 |
Hufeisen, SJ | 1 |
Popadak, BA | 1 |
Renock, SM | 1 |
Steinberg, S | 1 |
Ernsberger, P | 1 |
Jayathilake, K | 1 |
Meltzer, HY | 1 |
Roth, BL | 1 |
Kim, SF | 1 |
Huang, AS | 1 |
Snowman, AM | 1 |
Teuscher, C | 1 |
Snyder, SH | 1 |
Lange, JH | 1 |
Reinders, JH | 1 |
Tolboom, JT | 1 |
Glennon, JC | 1 |
Coolen, HK | 1 |
Kruse, CG | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
Orally-Disintegrating vs. Regular Olanzapine Tablets: Effects on Weight and GI Hormones[NCT00384332] | Phase 4 | 20 participants (Actual) | Interventional | 2007-01-31 | Completed | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
Montgomery Asberg Depression Rating Scale (MADRS) total score. Construct: Depression severity. Scores below represent mean change scores, endpoint minus baseline. Minimum total score: 0 (no depression). Maximum total score: 60 (severe depression). Lower (more negative) scores indicate a better outcome. There are no subscales. (NCT00384332)
Timeframe: 10 weeks
Intervention | units on a scale (Mean) |
---|---|
Arm 1 | -15.5 |
Arm 2 | -15.5 |
Change in weight from baseline to endpoint in kilograms. Reported as weight in Kilograms at Baseline, Weeks 1, 4, 6, and 8 (NCT00384332)
Timeframe: 10 weeks
Intervention | kilograms (Mean) | ||||
---|---|---|---|---|---|
Baseline | Week 1 | Week 4 | Week 6 | Week 8 | |
Arm 1- ODT | 76.0 | 77.4 | 77.8 | 78.9 | 79.1 |
Arm 2- SOT | 76.1 | 77.6 | 78.3 | 79.4 | 80.1 |
3 other studies available for quetiapine and Weight Gain
Article | Year |
---|---|
H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs.
Topics: Animals; Antipsychotic Agents; Discriminant Analysis; Drug Evaluation, Preclinical; Forecasting; Hum | 2003 |
From the Cover: Antipsychotic drug-induced weight gain mediated by histamine H1 receptor-linked activation of hypothalamic AMP-kinase.
Topics: Adenylate Kinase; Animals; Antipsychotic Agents; Enzyme Activation; Hypothalamus; Immunohistochemist | 2007 |
Principal component analysis differentiates the receptor binding profiles of three antipsychotic drug candidates from current antipsychotic drugs.
Topics: Antipsychotic Agents; Basal Ganglia Diseases; Benzoxazines; Biogenic Monoamines; Humans; Hyperprolac | 2007 |